Home › Lupus
Lupus clinical trials recruiting in the U.S.
74 studies for Lupus are recruiting participants at sites across the United States.
Lupus is an autoimmune disease that causes your immune system to attack your healthy tissues and cells. This can cause damage to many parts of your body.
Cities with the most studies
- New York City, NY18 studies
- Houston, TX14 studies
- Durham, NC12 studies
- Washington, DC11 studies
- Miami, FL10 studies
- Oklahoma City, OK9 studies
- San Diego, CA8 studies
- Tampa, FL8 studies
- Boston, MA8 studies
- Chicago, IL8 studies
- Philadelphia, PA8 studies
- Santa Monica, CA7 studies
- Plantation, FL7 studies
- Clearwater, FL7 studies
- Charlotte, NC7 studies
- Buena Park, CA7 studies
- Atlanta, GA7 studies
- Los Angeles, CA7 studies
- Memphis, TN6 studies
- Cedar Rapids, IA6 studies
- Dallas, TX6 studies
- Hollywood, FL5 studies
- Jackson, TN5 studies
- Lake Charles, LA5 studies
- St. Louis, MO5 studies
- New Rochelle, NY5 studies
- Cicero, IL5 studies
- Syracuse, NY5 studies
- Orlando, FL5 studies
- Mesquite, TX4 studies
- Frisco, TX4 studies
- Fullerton, CA4 studies
- New Orleans, LA4 studies
- Charleston, SC4 studies
- Kansas City, KS4 studies
- Louisville, KY4 studies
- Phoenix, AZ4 studies
- San Antonio, TX4 studies
- Coral Springs, FL4 studies
- El Paso, TX4 studies
By state
- Alabama5 studies
- Arizona7 studies
- California26 studies
- Colorado6 studies
- District of Columbia5 studies
- Florida23 studies
- Georgia9 studies
- Illinois14 studies
- Indiana3 studies
- Iowa6 studies
- Kansas4 studies
- Kentucky4 studies
- Louisiana8 studies
- Maryland11 studies
- Massachusetts9 studies
- Michigan10 studies
- Minnesota5 studies
- Missouri7 studies
- Montana3 studies
- Nebraska3 studies
- New Jersey6 studies
- New York25 studies
- North Carolina20 studies
- Ohio9 studies
- Oklahoma9 studies
- Pennsylvania13 studies
- South Carolina5 studies
- Tennessee12 studies
- Texas24 studies
- Utah4 studies
- Virginia3 studies
- Washington5 studies
Recently updated studies
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Nov 13, 2026 · NCT07430306A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Nov 12, 2026 · NCT07409181Pain Phenotyping of Rheumatic Diseases - An Observational Study
RecruitingObservational studyHealthy volunteers welcome
Ages 9 to 85 · All sexes · Updated Nov 12, 2026 · NCT07829497Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04751396Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03816345Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
RecruitingPhase 2/3
Ages 16 and older · All sexes · Updated Nov 10, 2026 · NCT07881120A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
RecruitingPhase 3
Ages 18 to 76 · All sexes · Updated Nov 10, 2026 · NCT07840287Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
RecruitingObservational study
Ages 18 to 120 · Women · Updated Nov 10, 2026 · NCT05567198Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Nov 9, 2026 · NCT06133972Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RecruitingObservational study
Ages 18 to 65 · Women · Updated Nov 6, 2026 · NCT06378736A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 4, 2026 · NCT07355218A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 4, 2026 · NCT07332481A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 3, 2026 · NCT07438496Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06434363A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RecruitingObservational study
Ages 16 and older · All sexes · Updated Nov 2, 2026 · NCT07175285A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Nov 2, 2026 · NCT07085104A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RecruitingPhase 3
Ages 16 and older · All sexes · Updated Nov 2, 2026 · NCT06617325Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
RecruitingPhase 2
Ages 12 to 65 · All sexes · Updated Oct 30, 2026 · NCT07053800Study of Systemic Lupus Erythematosus
RecruitingObservational studyHealthy volunteers welcome
Ages 3 to 120 · All sexes · Updated Oct 29, 2026 · NCT00001372Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Oct 28, 2026 · NCT07201558Safety of the Herpes Zoster Subunit Vaccine in Lupus
RecruitingPhase 4
Ages 18 to 90 · All sexes · Updated Oct 28, 2026 · NCT05559671Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
RecruitingPhase 1
Ages 18 to 60 · All sexes · Updated Oct 27, 2026 · NCT06975787A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Oct 26, 2026 · NCT06925542A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Oct 26, 2026 · NCT06613360A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Oct 20, 2026 · NCT07607964From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.